Month: December 2021

Release – Voyager Digital Announces Trading Of Common Shares And Variable Voting Shares Under Single Trading Symbol To Commence As Of Market Open On TSX On December 23, 2021

Posted on by Admin

 


Voyager Digital Announces Trading Of Common Shares And Variable Voting Shares Under Single Trading Symbol To Commence As Of Market Open On TSX On December 23, 2021

 

Research, News, and Market Data on Voyager Digital

 

NEW YORK, Dec. 20, 2021 /PRNewswire/ – Voyager Digital Ltd. (“Voyager” or the “Company”) (TSX: VOYG) (OTCQX: VYGVF) (FRA: UCD2), one of the fastest-growing, publicly traded cryptocurrency platforms in the United States, is pleased to announce that its amended share structure, overwhelmingly approved at the annual general and special meeting of shareholders held on December 14, 2021, will be reflected in trading effective as of the opening of the Market on the Toronto Stock Exchange on Thursday December 23, 2021. The amendment in share structure was implemented to ensure Voyager’s status as a Foreign Private Issuer and reduce compliance costs. The common shares (“Common Shares”) and its newly implemented variable voting shares (the “Variable Voting Shares”) will begin trading at the market opening on the Toronto Stock Exchange under the single and current ticker “VOYG”. These shares will bear the CUSIP/ISIN number 92919V405/CA92919V405 and will be designated for purposes of trading under the single designation of “Common and Variable Voting Shares” of Voyager.

At its annual general and special meeting of shareholders held on December 14, 2021, the shareholders of Voyager approved the amendment of its articles (the “Amended Articles”), as further described in its management information circular dated November 15, 2021 (the “Circular”), in order to, among other things:

  • Create and set the terms of a new class of shares of Voyager, being the Variable Voting Shares, including applying coattail terms to such shares; and
  • Amend the terms of the existing Common Shares, including without limitation, by amending the requirements on who may hold Common Shares, which is limited to non-US persons, and applying coattail terms to such shares.

Details of the changes in share structure can be found in the Circular, available under Voyager’s profile at www.sedar.com.

In connection with the Amended Articles, Voyager has applied for, and has received certain exemptive relief (the “Decision”) from the Canadian securities administrators to enable its Common Shares and Variable Voting Shares to be treated collectively as if they were a single class for certain purposes, including for take-over bid and early warning reporting purposes and to permit the Company to refer to the variable voting shares as variable voting shares.

A copy of the Circular, the Amended Articles and the Decision are available on SEDAR at www.sedar.com  under Voyager’s profile. 

About Voyager Digital Ltd.
Publicly traded Voyager Digital Ltd.’s (TSX: VOYG) (OTCQX: VYGVF) (FRA: UCD2) US subsidiary, Voyager Digital, LLC, is a fast-growing, cryptocurrency platform in the United States founded in 2018 to bring choice, transparency, and cost efficiency to the marketplace. Voyager offers a secure way to trade over 70 different crypto assets using its easy-to-use mobile application and earn rewards up to 12 percent annually on more than 30 cryptocurrencies. Through its subsidiary Coinify ApS, Voyager provides crypto payment solutions for both consumers and merchants around the globe. To learn more about the company, please visit https://www.investvoyager.com.

The TSX has not approved or disapproved of the information contained herein.

Press Contacts

Voyager Digital, Ltd.
Michael Legg
Chief Communications Officer
(212) 547-8807
mlegg@investvoyager.com

Voyager Public Relations Team
pr@investvoyager.com

SOURCE Voyager Digital (Canada) Ltd.

Related Links

https://www.investvoyager.com/

Voyager Digital Announces Trading Of Common Shares And Variable Voting Shares Under Single Trading Symbol To Commence As Of Market Open On TSX On December 23, 2021

Posted on by Admin

 


Voyager Digital Announces Trading Of Common Shares And Variable Voting Shares Under Single Trading Symbol To Commence As Of Market Open On TSX On December 23, 2021

 

Research, News, and Market Data on Voyager Digital

 

NEW YORK, Dec. 20, 2021 /PRNewswire/ – Voyager Digital Ltd. (“Voyager” or the “Company”) (TSX: VOYG) (OTCQX: VYGVF) (FRA: UCD2), one of the fastest-growing, publicly traded cryptocurrency platforms in the United States, is pleased to announce that its amended share structure, overwhelmingly approved at the annual general and special meeting of shareholders held on December 14, 2021, will be reflected in trading effective as of the opening of the Market on the Toronto Stock Exchange on Thursday December 23, 2021. The amendment in share structure was implemented to ensure Voyager’s status as a Foreign Private Issuer and reduce compliance costs. The common shares (“Common Shares”) and its newly implemented variable voting shares (the “Variable Voting Shares”) will begin trading at the market opening on the Toronto Stock Exchange under the single and current ticker “VOYG”. These shares will bear the CUSIP/ISIN number 92919V405/CA92919V405 and will be designated for purposes of trading under the single designation of “Common and Variable Voting Shares” of Voyager.

At its annual general and special meeting of shareholders held on December 14, 2021, the shareholders of Voyager approved the amendment of its articles (the “Amended Articles”), as further described in its management information circular dated November 15, 2021 (the “Circular”), in order to, among other things:

  • Create and set the terms of a new class of shares of Voyager, being the Variable Voting Shares, including applying coattail terms to such shares; and
  • Amend the terms of the existing Common Shares, including without limitation, by amending the requirements on who may hold Common Shares, which is limited to non-US persons, and applying coattail terms to such shares.

Details of the changes in share structure can be found in the Circular, available under Voyager’s profile at www.sedar.com.

In connection with the Amended Articles, Voyager has applied for, and has received certain exemptive relief (the “Decision”) from the Canadian securities administrators to enable its Common Shares and Variable Voting Shares to be treated collectively as if they were a single class for certain purposes, including for take-over bid and early warning reporting purposes and to permit the Company to refer to the variable voting shares as variable voting shares.

A copy of the Circular, the Amended Articles and the Decision are available on SEDAR at www.sedar.com  under Voyager’s profile. 

About Voyager Digital Ltd.
Publicly traded Voyager Digital Ltd.’s (TSX: VOYG) (OTCQX: VYGVF) (FRA: UCD2) US subsidiary, Voyager Digital, LLC, is a fast-growing, cryptocurrency platform in the United States founded in 2018 to bring choice, transparency, and cost efficiency to the marketplace. Voyager offers a secure way to trade over 70 different crypto assets using its easy-to-use mobile application and earn rewards up to 12 percent annually on more than 30 cryptocurrencies. Through its subsidiary Coinify ApS, Voyager provides crypto payment solutions for both consumers and merchants around the globe. To learn more about the company, please visit https://www.investvoyager.com.

The TSX has not approved or disapproved of the information contained herein.

Press Contacts

Voyager Digital, Ltd.
Michael Legg
Chief Communications Officer
(212) 547-8807
mlegg@investvoyager.com

Voyager Public Relations Team
pr@investvoyager.com

SOURCE Voyager Digital (Canada) Ltd.

Related Links

https://www.investvoyager.com/

Reducing the Cost of Producing Rare Earth Metals

Posted on by Admin 


	Image Credit: Terence Wright (Flickr)

Fewer Greenhouse Gases and Lower Capital Costs to Separate Rare Metals

 

Becky Ham | MIT News

New processing methods developed by MIT researchers could help ease looming shortages of the essential metals that power everything from phones to automotive batteries by making it easier to separate these rare metals from mining ores and recycled materials.

Selective adjustments within a chemical process called sulfidation allowed professor of metallurgy Antoine Allanore and his graduate student Caspar Stinn to successfully target and separate rare metals, such as the cobalt in a lithium-ion battery, from mixed-metal materials.

As they report in the journal Nature, their processing techniques allow the metals to remain in solid form and be separated without dissolving the material. This avoids traditional but costly liquid separation methods that require significant energy. The researchers developed processing conditions for 56 elements and tested these conditions on 15 elements.

Their sulfidation approach, they write in the paper, could reduce the capital costs of metal separation between 65 and 95 percent from mixed-metal oxides. Their selective processing could also reduce greenhouse gas emissions by 60 to 90 percent compared to traditional liquid-based separation.

“We were excited to find replacements for processes that had really high levels of water usage and greenhouse gas emissions, such as lithium-ion battery recycling, rare-earth magnet recycling, and rare-earth separation,” says Stinn. “Those are processes that make materials for sustainability applications, but the processes themselves are very unsustainable.”

The findings offer one way to alleviate a growing demand for minor metals like cobalt, lithium, and rare earth elements that are used in “clean” energy products like electric cars, solar cells, and electricity-generating windmills. According to a 2021 report by the International Energy Agency, the average amount of minerals needed for a new unit of power generation capacity has risen by 50 percent since 2010, as renewable energy technologies using these metals expand their reach.

 

Opportunity for Selectivity

For more than a decade, the Allanore group has been studying the use of sulfide materials in developing new electrochemical routes for metal production. Sulfides are common materials, but the MIT scientists are experimenting with them under extreme conditions like very high temperatures — from 800 to 3,000 degrees Fahrenheit — that are used in manufacturing plants but not in a typical university lab.

“We are looking at very well-established materials in conditions that are uncommon compared to what has been done before,” Allanore explains, “and that is why we are finding new applications or new realities.”

In the process of synthetizing high-temperature sulfide materials to support electrochemical production, Stinn says, “we learned we could be very selective and very controlled about what products we made. And it was with that understanding that we realized, ‘OK, maybe there’s an opportunity for selectivity in separation here.’”

The chemical reaction exploited by the researchers reacts a material containing a mix of metal oxides to form new metal-sulfur compounds or sulfides. By altering factors like temperature, gas pressure, and the addition of carbon in the reaction process, Stinn and Allanore found that they could selectively create a variety of sulfide solids that can be physically separated by a variety of methods, including crushing the material and sorting different-sized sulfides or using magnets to separate different sulfides from one another.

Current methods of rare metal separation rely on large quantities of energy, water, acids, and organic solvents which have costly environmental impacts, says Stinn. “We are trying to use materials that are abundant, economical, and readily available for sustainable materials separation, and we have expanded that domain to now include sulfur and sulfides.”

Stinn and Allanore used selective sulfidation to separate out economically important metals like cobalt in recycled lithium-ion batteries. They also used their techniques to separate dysprosium — a rare-earth element used in applications ranging from data storage devices to optoelectronics — from rare-earth-boron magnets or from the typical mixture of oxides available from mining minerals such as bastnaesite.

 

Leveraging Existing Technology

Metals like cobalt and rare earths are only found in small amounts in mined materials, so industries must process large volumes of material to retrieve or recycle enough of these metals to be economically viable, Allanore explains. “It’s quite clear that these processes are not efficient. Most of the emissions come from the lack of selectivity and the low concentration at which they operate.”

By eliminating the need for liquid separation and the extra steps and materials it requires to dissolve and then reprecipitate individual elements, the MIT researchers’ process significantly reduces the costs incurred and emissions produced during separation.

“One of the nice things about separating materials using sulfidation is that a lot of existing technology and process infrastructure can be leveraged,” Stinn says. “It’s new conditions and new chemistries in established reactor styles and equipment.”

The next step is to show that the process can work for large amounts of raw material — separating out 16 elements from rare-earth mining streams, for example. “Now we have shown that we can handle three or four or five of them together, but we have not yet processed an actual stream from an existing mine at a scale to match what’s required for deployment,” Allanore says.

Stinn and colleagues in the lab have built a reactor that can process about 10 kilograms of raw material per day, and the researchers are starting conversations with several corporations about the possibilities.

“We are discussing what it would take to demonstrate the performance of this approach with existing mineral and recycling streams,” Allanore says.

 

Suggested Reading:



Rare Earth Elements Demand is Still Growing

What’s in Infrastructure Bill for Rare Earth Metals?





Outlook Good For Base and Precious Metals Mining Stocks

How Do Gold Royalty Companies Work?

 

Stay up to date. Follow us:

 

Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders

Posted on by Admin


Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders

 

  • Genentech Will Pay Lineage $50 Million Upfront
  • Eligible to Receive a Total of $670 Million in Upfront and Milestone Payments
  • Conference Call to Discuss Collaboration Planned for 8 a.m. ET

CARLSBAD, Calif.–(BUSINESS WIRE)–Dec. 20, 2021– 

Lineage Cell Therapeutics, Inc.
 (NYSE American and TASE: LCTX), today announced that Lineage and its subsidiary, 
Cell Cure Neurosciences Ltd., have entered into an exclusive worldwide collaboration and license agreement with Roche and 

Genentech
, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), for the development and commercialization of a retinal pigment epithelium (RPE) cell therapy for the treatment of ocular disorders, including advanced dry age-related macular degeneration (dry AMD) with geographic atrophy (GA).

Genentech will assume responsibility for further clinical development and commercialization of Lineage’s OpRegen program, which currently is being evaluated in a Phase 1/2a open-label, dose escalation clinical safety and efficacy study in patients with advanced dry AMD with GA. Under the terms of the collaboration agreement, Lineage will complete activities related to the ongoing clinical study, for which enrollment is complete, and perform certain manufacturing activities. 
Genentech will pay Lineage a 
$50 million upfront payment and Lineage is eligible to receive up to 
$620 million in additional development, approval and sales milestone payments, in addition to tiered double- digit royalties.

“Genentech is a clear global leader in ophthalmology and has demonstrated a longstanding commitment to patients, innovative research and successful product development,” said  Brian M. Culley, Lineage’s CEO. “Their desire to combine our cell therapy technology with their ophthalmology expertise and capabilities will help advance the OpRegen program more rapidly and we believe successfully to patients with serious ocular disorders, such as dry age-related macular degeneration. Lineage’s objective is to pioneer a new branch of regenerative medicine, based on transplanting whole cells into the body to restore activity lost to aging, injury or disease. We believe the results we have demonstrated to date with OpRegen represent a paradigm change many did not believe possible with cell therapy, by restoring retinal tissue and potentially halting or reversing the expansion of geographic atrophy. I am incredibly proud of what the Lineage team has accomplished with the OpRegen program and look forward to joining forces with the 
Genentech team as they work to take this program to the next level and potentially to patients in need of treatment.”

Mr. Culley continued, “Looking ahead, Lineage will remain focused on advancing our spinal cord injury and oncology programs as well as announcing new disease settings where we plan to deploy our technology, either on our own or through strategic alliances. All of us at Lineage are immensely proud to have the opportunity and responsibility to advance a new and exciting branch of medicine, and our aim is to make a profound impact on the patients who serve as our inspiration.”

“Genentech has a longstanding commitment to discovering and developing novel drugs for the treatment of serious eye disorders such as with advanced dry AMD with GA, which is one of our focus areas within ophthalmology,” said  James Sabry, M.D., Ph.D., global head of Pharma Partnering, Roche. “We are excited to partner with 
Lineage Cell Therapeutics to advance potential new therapies in an area of high unmet medical need.”

Conference Call Information

Lineage will host a live conference call and webcast today beginning at 
8 a.m. ET to discuss the collaboration with the Roche Group and 
Genentech. Interested parties may access the conference call by dialing (866) 888-8633 from the 
U.S. and 
Canada and (636) 812-6629 from elsewhere outside the 
U.S. and 
Canada and should request the “Lineage Cell Therapeutics Call”. A live webcast of the conference call will be available online in the Investors section of Lineage’s website. A replay of the webcast will be available on Lineage’s website for 30 days and a telephone replay will be available through 
December 27, 2021, by dialing (855) 859-2056 from the 
U.S. and 
Canada and (404) 537-3406 from elsewhere outside the 
U.S. and 
Canada and entering conference ID number 5174206.

About OpRegen

OpRegen has been developed in part through contributions and financial grants made by 
Hadasit Medical Research Services and Development Ltd. (“Hadasit”) and the 
Israeli Innovation Authority (the “IIA”). Lineage is obligated to pay a portion of upfront, milestone and royalty payments it receives to Hadasit and the IIA. OpRegen is currently being evaluated in a Phase 1/2a open-label, dose escalation safety and efficacy study of a single injection of human retinal pigment epithelium cells derived from an established pluripotent cell line and transplanted subretinally in patients with advanced dry AMD with GA. The study enrolled 24 patients into 4 cohorts. The first 3 cohorts enrolled only legally blind patients with a best corrected visual acuity (BCVA) of 20/200 or worse. The fourth cohort enrolled 12 better vision patients (BCVA from 20/65 to 20/250 with smaller mean areas of GA). Cohort 4 also included patients treated with a new “thaw-and-inject” formulation of OpRegen, which can be shipped directly to sites and used immediately upon thawing, removing the complications and logistics of having to use a dose preparation facility. The primary objective of the study was to evaluate the safety and tolerability of OpRegen as assessed by the incidence and frequency of treatment emergent adverse events. Secondary objectives are to evaluate the preliminary efficacy of OpRegen treatment by assessing the changes in ophthalmological parameters measured by various methods of primary clinical relevance. OpRegen has been well tolerated to date and there have been no new, unexpected ocular or systemic adverse events or serious adverse events related to OpRegen or study procedures that have not been previously reported.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “aim,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “can,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to the collaboration and license agreement with Roche and 
Genentech and activities expected to occur under the collaboration and license agreement, the upfront, milestone and royalty consideration payable to Lineage, the potential benefits of treatment with OpRegen, and Lineage’s plans to advance its spinal cord injury and oncology programs and announce new disease settings where it plans to deploy its technology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including the risk that competing alternative therapies may adversely impact the commercial potential of OpRegen, which could materially adversely affect the milestone and royalty payments payable to Lineage under the collaboration and license agreement, the risk that Roche and 
Genentech may not be successful in completing further clinical trials for OpRegen and/or obtaining regulatory approval for OpRegen in any particular jurisdiction, and risks and uncertainties inherent in Lineage’s business and other risks in Lineage’s filings with the 
Securities and Exchange Commission (SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the 
SEC, including Lineage’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the 
SEC and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(ir@lineagecell.com)
(442) 287-8963

Solebury Trout IR
Mike Biega
(Mbiega@soleburytrout.com)
(617) 221-9660

Russo Partners – Media Relations
Nic Johnson or  David Schull
Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com
(212) 845-4242

Source: 
Lineage Cell Therapeutics, Inc.

QuickChek – December 20, 2021

Posted on by Admin



Indonesia Energy Daily Production Rate Increases Over 50% With Recently Completed “Kruh 26” Well

Indonesia Energy announced that its daily oil production rate has increased over 50% as a result of the recently completed “Kruh 26” well on its 63,000-acre Kruh Block

Research, News & Market Data on Indonesia Energy

Watch recent presentation from Indonesia Energy



Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders

Lineage Cell Therapeutics announced that Lineage and its subsidiary, Cell Cure Neurosciences Ltd., have entered into an exclusive worldwide collaboration

Research, News & Market Data on Lineage

Watch recent presentation from Lineage



Orion Group Holdings, Inc. Announces Contract Awards of Approximately $33 Million

Orion Group Holdings announced two contract awards for its Marine segment totaling approximately $33 million

Research, News & Market Data on Orion Group Holdings

Watch recent presentation from Orion Group Holdings



Voyager Digital Announces Brian Brooks, Former Acting Comptroller of the U.S. Currency, Joins Board of Directors

Voyager Digital announced that Brian Brooks has been appointed to Voyager Digital Ltd’s Board of Directors effective immediately

Voyager Digital Announces Trading of Common Shares and Variable Voting Shares Under Single Trading Symbol to Commence as of Market Open on TSX on December 23, 2021

Voyager Digital announced that its amended share structure, overwhelmingly approved at the annual general and special meeting of shareholders held on December 14, 2021, will be reflected in trading effective as of the opening of the Market on the Toronto Stock Exchange on Thursday December 23, 2021

Research, News & Market Data on Voyager Digital

Watch recent presentation from Voyager Digital

 

Stay up to date. Follow us:

 

Release – Orion Group Holdings, Inc. Announces Contract Awards of Approximately $33 Million

Posted on by Admin

 


Orion Group Holdings, Inc. Announces Contract Awards of Approximately $33 Million

Research, News, and Market Data on Orion Group Holdingsl

 

HOUSTON–(BUSINESS WIRE)–Dec. 20, 2021– 
Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”) a leading specialty construction company, today announced two contract awards for its Marine segment totaling approximately 
$33 million.

The Company was recently awarded a 
$28.3 million design-bid-build contract by the Naval Facilities Engineering Command (“NAVFAC”) Southeast for the repair and update of an existing waterside facility in the 
Bahamas. Work on the project site is scheduled to commence in the second quarter of 2022 and to be completed in early 2024.

The Company has also been awarded a contract valued at 
$4.4 million to rehabilitate an existing barge dock for a private sector energy client along the gulf coast of 
Texas. Work is expected to begin during the first quarter of 2022 and be completed during the third quarter of 2022.

“The award from NAVFAC continues our long history of supporting the 
U.S. Navy’s infrastructure needs,” said  Mark Stauffer, Orion’s President and Chief Executive Officer. “Additionally, we are pleased to continue to be the market leader supporting the needs of our energy sector clients along the 
Texas gulf coast.”

About Orion Group Holdings

Orion Group Holdings, Inc., a leading specialty construction company serving the infrastructure, industrial and building sectors, provides services both on and off the water in the continental 
United States, 
Alaska, 
Canada and the 
Caribbean Basin through its marine segment and its concrete segment. The Company’s marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. Its concrete segment provides turnkey concrete construction services including pour and finish, dirt work, layout, forming, rebar, and mesh across the light commercial, structural and other associated business areas. The Company is headquartered in 
Houston, Texas with regional offices throughout its operating areas.

Forward-Looking Statements

The matters discussed in this press release may constitute or include projections or other forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the provisions of which the Company is availing itself. Certain forward-looking statements can be identified by the use of forward-looking terminology, such as ‘believes’, ‘expects’, ‘may’, ‘will’, ‘could’, ‘should’, ‘seeks’, ‘approximately’, ‘intends’, ‘plans’, ‘estimates’, or ‘anticipates’, or the negative thereof or other comparable terminology, or by discussions of strategy, plans, objectives, intentions, estimates, forecasts, outlook, assumptions, or goals. In particular, statements regarding future operations or results, including those set forth in this press release and any other statement, express or implied, concerning future operating results or the future generation of or ability to generate revenues, income, net income, profit, EBITDA, EBITDA margin, or cash flow, including to service debt, and including any estimates, forecasts or assumptions regarding future revenues or revenue growth, are forward-looking statements. Forward looking statements also include estimated project start date, anticipated revenues, and contract options which may or may not be awarded in the future. Forward looking statements involve risks, including those associated with the Company’s fixed price contracts that impacts profits, unforeseen productivity delays that may alter the final profitability of the contract, cancellation of the contract by the customer for unforeseen reasons, delays or decreases in funding by the customer, levels and predictability of government funding or other governmental budgetary constraints and any potential contract options which may or may not be awarded in the future, and are the sole discretion of award by the customer. Past performance is not necessarily an indicator of future results. In light of these and other uncertainties, the inclusion of forward-looking statements in this press release should not be regarded as a representation by the Company that the Company’s plans, estimates, forecasts, goals, intentions, or objectives will be achieved or realized. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update information contained in this press release whether as a result of new developments or otherwise.

Please refer to the Company’s Annual Report on Form 10-K, filed on 
March 2, 2021, which is available on its website at www.oriongroupholdingsinc.com or at the SEC’s website at www.sec.gov, for additional and more detailed discussion of risk factors that could cause actual results to differ materially from our current expectations, estimates or forecasts.

Orion Group Holdings Inc.
Francis Okoniewski, Vice President Investor Relations
(346) 616-4138
fokoniewski@orn.net
www.oriongroupholdingsinc.com

Source: 
Orion Group Holdings, Inc.

Release – Indonesia Energy Daily Production Rate Increases Over 50 With Recently Completed Kruh 26 Well

Posted on by Admin


Indonesia Energy Daily Production Rate Increases Over 50% With Recently Completed “Kruh 26” Well

 

Additional well drilling on the Kruh Block anticipated to commence within 60 Days

JAKARTA, INDONESIA and DANVILLE, CA / ACCESSWIRE / December 20, 2021 / Indonesia Energy Corporation Limited (NYSE American:INDO) (IEC), an oil and gas exploration and production company focused on Indonesia, today announced that its daily oil production rate has increased over 50% as a result of the recently completed “Kruh 26” well on its 63,000-acre Kruh Block.

IEC’s average daily production rate over the first 10 months of 2021 was approximately 160 barrels of oil per day. Since completion of the Kruh 26 well, IEC has been averaging production of approximately 245 barrels of oil per day. IEC anticipates that as the Kruh 26 well continues to de-water, its production rate of oil is expected to increase.

In a further update to its previously announced Kruh Block drilling program for 2021, IEC announced that its “Kruh 25” well is currently shut-in as a result of significant damage due to flooding during an extended period of heavy monsoon rain leading to extremely difficult working conditions caused by a deteriorated drill site and inadequate equipment performance. Kruh-25 will be the subject of remedial workover activities so that it can attempt to match the results of the Kruh-26 well.

After evaluation of the successful results from the Kruh-26 well, IEC now plans to commence drilling two back-to-back producing wells at Kruh Block commencing in approximately 60 days. IEC’s production target is to be producing approximately 450 barrels of oils per day after completion of these next two wells. IEC also plans to commence drilling on two additional wells at Kruh Block during the third quarter of 2022.

These new wells are part of IEC’s overall previously announced plan to drill a total of 18 new wells on the Kruh Block over the next 3 years. In order to help meet its drilling plan goals for Kruh Block, IEC is in the process of completing plans to conduct a 30KM seismic program on the Kruh Block which should help to optimize well selection.

The Kruh 26 well cost approximately $1.5 million to drill and complete (exactly matching the planned drilling budget). Based on the terms of IEC’s contract with the Indonesian government and an assumed oil price of $73 per barrel (the current price), this well is expected to generate approximately $1.5 million in net revenue in its first year, which is enough to recover the cost to drill such well.

Mr. Frank Ingriselli, IEC’s President, commented “We are excited with the results of the Kruh 26 well which has led to a more than 50% increase in our overall daily production. This progress moves our company closer to a cash flow positive position and sets the stage for significant future growth. We believe Kruh Block is a world class asset that should significantly grow our cash flow as we drill additional wells and seek to maximize returns on our investments and grow shareholder value.”

About Indonesia Energy Corporation Limited

Indonesia Energy Corporation Limited (NYSE American: INDO) is a publicly traded energy company engaged in the acquisition and development of strategic, high growth energy projects in Indonesia. IEC’s principal assets are its Kruh Block (63,000 acres) located onshore on the Island of Sumatra in Indonesia and its Citarum Block (1,000,000 acres) located onshore on the Island of Java in Indonesia. IEC is headquartered in Jakarta, Indonesia and has a representative office in Danville, California. For more information on IEC, please visit www.indo-energy.com.

Cautionary Statement Regarding Forward-Looking Statements

All statements in this press release of Indonesia Energy Corporation Limited (“IEC”) and its representatives and partners that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Acts”). In particular, when used in the preceding discussion, the words “estimates,” “believes,” “hopes,” “expects,” “intends,” “on-track”, “plans,” “anticipates,” or “may,” and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Acts and are subject to the safe harbor created by the Acts. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the IEC’s control, that could cause actual results (including, without limitation, the anticipated results of IEC’s exploration and production activities and the impact of such activities on IEC’s results of operations as descried herein) to materially and adversely differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth in the Risk Factors section of the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2020, filed on May 18, 2021, with the Securities and Exchange Commission (SEC). Copies are of such documents are available on the SEC’s website, www.sec.gov. IEC undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Company Contact:

Frank C. Ingriselli
President, Indonesia Energy Corporation Limited
Frank.Ingriselli@Indo-Energy.com

SOURCE: Indonesia Energy Corporation Limited

Voyager Digital Announces Brian Brooks, Former Acting Comptroller of the U.S. Currency, Joins Board of Directors

Posted on by Admin

 


Voyager Digital Announces Brian Brooks, Former Acting Comptroller of the U.S. Currency, Joins Board of Directors

 

Research, News, and Market Data on Voyager Digital

 

Voyager Digital Ltd. (“Voyager” or the “Company”) (TSX: VOYG; OTCQX: VYGVF; FRA: UCD2), one of the fastest-growing, publicly traded cryptocurrency platforms in the United States, is pleased to announce Brian Brooks has been appointed to Voyager Digital Ltd’s Board of Directors effective immediately.
 
Philip Eytan, Chairman of Voyager Digital, said, “On behalf of the Board, I welcome Brian to the Board as an independent, non-executive Director.”  Mr. Eytan continued, “Brian’s extensive background as an executive at major crypto companies and as the leader of important government regulatory initiatives in the crypto space will help propel the growth of digital assets and Voyager’s business.”

Brian is currently CEO of Bitfury Group Ltd and was formerly the Acting Comptroller of the U.S. Currency at the Office of the Comptroller of the Currency and, before that, the Chief Legal Officer of Coinbase. Mr. Brooks has also held senior positions in the traditional finance sector, including as EVP, General Counsel and Corporate Secretary at Fannie Mae and as Vice Chairman of OneWest Bank, N.A.

Mr. Brooks is a globally recognized leader in financial services law, operations, and policy and has been instrumental in the growth of several high-profile Silicon Valley fintech startups. He most recently appeared with other crypto CEOs before the House Committee on Financial Services to discuss cryptocurrencies.  His work as Acting Comptroller leading the U.S. national banking system earned him recognition on various lists of thought leaders, including as Cointelegraph’s 13th most influential person in crypto globally; as one of Qredo’s top 20 crypto regulatory voices; and as the 10th most important influencer in the world as rated by Crunchbase.

About Voyager Digital Ltd.

Publicly traded Voyager Digital Ltd.’s (TSX: VOYG) (OTCQX:VYGVF) (FRA: UCD2) US subsidiary, Voyager Digital, LLC, is a fast-growing, cryptocurrency platform in the United States founded in 2018 to bring choice, transparency, and cost efficiency to the marketplace. Voyager offers a secure way to trade over 70 different crypto assets using its easy-to-use mobile application and earn rewards up to 12 percent annually on more than 30 cryptocurrencies. Through its subsidiary Coinify ApS, Voyager provides crypto payment solutions for both consumers and merchants around the globe. To learn more about the company, please visit https://www.investvoyager.com.
 
The TSX has not approved or disapproved of the information contained herein.
 
SOURCE Voyager Digital, Ltd.

Press Contacts
 
Voyager Digital, Ltd.
Michael Legg
Chief Communications Officer
(212) 547-8807
mlegg@investvoyager.com

Voyager Public Relations Team
pr@investvoyager.com

Orion Group Holdings, Inc. Announces Contract Awards of Approximately $33 Million

Posted on by Admin

 


Orion Group Holdings, Inc. Announces Contract Awards of Approximately $33 Million

Research, News, and Market Data on Orion Group Holdingsl

 

HOUSTON–(BUSINESS WIRE)–Dec. 20, 2021– 
Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”) a leading specialty construction company, today announced two contract awards for its Marine segment totaling approximately 
$33 million.

The Company was recently awarded a 
$28.3 million design-bid-build contract by the Naval Facilities Engineering Command (“NAVFAC”) Southeast for the repair and update of an existing waterside facility in the 
Bahamas. Work on the project site is scheduled to commence in the second quarter of 2022 and to be completed in early 2024.

The Company has also been awarded a contract valued at 
$4.4 million to rehabilitate an existing barge dock for a private sector energy client along the gulf coast of 
Texas. Work is expected to begin during the first quarter of 2022 and be completed during the third quarter of 2022.

“The award from NAVFAC continues our long history of supporting the 
U.S. Navy’s infrastructure needs,” said  Mark Stauffer, Orion’s President and Chief Executive Officer. “Additionally, we are pleased to continue to be the market leader supporting the needs of our energy sector clients along the 
Texas gulf coast.”

About Orion Group Holdings

Orion Group Holdings, Inc., a leading specialty construction company serving the infrastructure, industrial and building sectors, provides services both on and off the water in the continental 
United States, 
Alaska, 
Canada and the 
Caribbean Basin through its marine segment and its concrete segment. The Company’s marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. Its concrete segment provides turnkey concrete construction services including pour and finish, dirt work, layout, forming, rebar, and mesh across the light commercial, structural and other associated business areas. The Company is headquartered in 
Houston, Texas with regional offices throughout its operating areas.

Forward-Looking Statements

The matters discussed in this press release may constitute or include projections or other forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the provisions of which the Company is availing itself. Certain forward-looking statements can be identified by the use of forward-looking terminology, such as ‘believes’, ‘expects’, ‘may’, ‘will’, ‘could’, ‘should’, ‘seeks’, ‘approximately’, ‘intends’, ‘plans’, ‘estimates’, or ‘anticipates’, or the negative thereof or other comparable terminology, or by discussions of strategy, plans, objectives, intentions, estimates, forecasts, outlook, assumptions, or goals. In particular, statements regarding future operations or results, including those set forth in this press release and any other statement, express or implied, concerning future operating results or the future generation of or ability to generate revenues, income, net income, profit, EBITDA, EBITDA margin, or cash flow, including to service debt, and including any estimates, forecasts or assumptions regarding future revenues or revenue growth, are forward-looking statements. Forward looking statements also include estimated project start date, anticipated revenues, and contract options which may or may not be awarded in the future. Forward looking statements involve risks, including those associated with the Company’s fixed price contracts that impacts profits, unforeseen productivity delays that may alter the final profitability of the contract, cancellation of the contract by the customer for unforeseen reasons, delays or decreases in funding by the customer, levels and predictability of government funding or other governmental budgetary constraints and any potential contract options which may or may not be awarded in the future, and are the sole discretion of award by the customer. Past performance is not necessarily an indicator of future results. In light of these and other uncertainties, the inclusion of forward-looking statements in this press release should not be regarded as a representation by the Company that the Company’s plans, estimates, forecasts, goals, intentions, or objectives will be achieved or realized. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update information contained in this press release whether as a result of new developments or otherwise.

Please refer to the Company’s Annual Report on Form 10-K, filed on 
March 2, 2021, which is available on its website at www.oriongroupholdingsinc.com or at the SEC’s website at www.sec.gov, for additional and more detailed discussion of risk factors that could cause actual results to differ materially from our current expectations, estimates or forecasts.

Orion Group Holdings Inc.
Francis Okoniewski, Vice President Investor Relations
(346) 616-4138
fokoniewski@orn.net
www.oriongroupholdingsinc.com

Source: 
Orion Group Holdings, Inc.

Stem Holdings (STMH)(STEM:CA) – What Do Friday’s Announcements Mean?

Posted on by Admin

Monday, December 20, 2021

Stem Holdings (STMH)(STEM:CA)
What Do Friday’s Announcements Mean?

Stem Holdings Inc is engaged in the purchasing, improving, and leasing of properties and finance assets which are operated by third parties and are used for the cultivation and retail sale of marijuana. Its properties includes 42nd Street, and Mulino Farm which are used for agriculture. The company generates its revenue in the form of rental income from tenants.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    New Direction. After the market close on Friday, Stem Holdings announced it is divesting Driven Deliveries, the e-commerce and delivery platform that was acquired about twelve months ago. According to the press release, the move is a reflection of significantly increased competition in the key California market and reduced price per pound for cannabis, resulting in a consistent low margin business.

    Management Changes.  In addition, Adam Berk resigned as CEO, effective immediately. Co-founder and current CFO Steve Hubbard has been named interim CEO. Mr. Berk’s resignation comes on the heels of the late November departure of COO Ellen Deutsch …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Low-Cost Materials Could Provide Instant Infection Test for Covid and Other Viruses

Posted on by Admin 


	Image Credit: Kentucky National Guard (Flickr)

A Sensor Based on Quantum Physics Would Detect SARS-CoV-2 Virus Instantly

 

David L. Chandler | 
MIT
News Office

A novel approach to testing for the presence of the virus that causes Covid-19 may lead to tests that are faster, less expensive, and potentially less prone to erroneous results than existing detection methods. Though the work, based on quantum effects, is still theoretical, these detectors could potentially be adapted to detect virtually any virus, the researchers say.

The new approach is described in a paper published Thursday in the journal Nano Letters, by Changhao Li, an MIT doctoral student; Paola Cappellaro, a professor of nuclear science and engineering and of physics; and Rouholla Soleyman and Mohammad Kohandel of the University of Waterloo.

Existing tests for the SARS-CoV-2 virus include rapid tests that detect specific viral proteins, and polymerase chain reaction (PCR) tests that take several hours to process. Neither of these tests can quantify the amount of virus present with high accuracy. Even the gold-standard PCR tests might have false-negative rates of more than 25 percent. In contrast, the team’s analysis shows the new test could have false negative rates below 1 percent. The test could also be sensitive enough to detect just a few hundred strands of the viral RNA, within just a second.

The new approach makes use of atomic-scale defects in tiny bits of diamond, known as nitrogen vacancy (NV) centers. These tiny defects are extremely sensitive to minute perturbations, thanks to quantum effects taking place in the diamond’s crystal lattice and are being explored for a wide variety of sensing devices that require high sensitivity.

The new method would involve coating the nanodiamonds containing these NV centers with a material that is magnetically coupled to them and has been treated to bond only with the specific RNA sequence of the virus. When the virus RNA is present and bonds to this material, it disrupts the magnetic connection and causes changes in the diamond’s fluorescence that are easily detected with a laser-based optical sensor.

The sensor uses only low-cost materials (the diamonds involved are smaller than specks of dust), and the devices could be scaled up to analyze a whole batch of samples at once, the researchers say. The gadolinium-based coating with its RNA-tuned organic molecules can be produced using common chemical processes and materials, and the lasers used to read out the results are comparable to cheap, widely available commercial green laser pointers.

While this initial work was based on detailed mathematical simulations that proved the system can work in principle, the team is continuing to work on translating that into a working lab-scale device to confirm the predictions. “We don’t know how long it will take to do the final demonstration,” Li says. Their plan is first to do a basic proof-of-principle lab test, and then to work on ways to optimize the system to make it work on real virus diagnosis applications.

 

Using mathematical simulations, researchers have shown it’s possible to design a sensor to detect SARS-CoV-2 virus

 

The multidisciplinary process requires a combination of expertise in quantum physics and engineering, for producing the detectors themselves, and in chemistry and biology, for developing the molecules that bind with the viral RNA and for finding ways to bond these to the diamond surfaces.

Even if complications arise in translating the theoretical analysis into a working device, Cappellaro says, there is such a large margin of lower false negatives predicted from this work that it will likely still have a strong advantage over standard PCR tests in that regard. And even if the accuracy were the same, this method would still have a major advantage in producing its results with a matter of minutes, rather than requiring several hours, she says.

The basic method can be adapted to any virus, she says, including any new ones that may arise, simply by adapting the compounds that are attached to the nanodiamond sensors to match the generic material of the specific target virus.

“The proposed approach is appealing both for its generality and its technological simplicity,” says David Glenn, senior research scientist at Quantum Diamond Technologies Inc., who was not associated with this work. “In particular, the sensitive, all-optical detection technique described here requires minimal instrumentation compared to other methods that employ nitrogen vacancy centers,” he says.

He adds that for his company, “we’re very excited about using diamond-based quantum sensors to build powerful tools for biomedical diagnostics. Needless to say, we will be following along with great interest as the ideas presented in this work are translated to the lab.”

 

Suggested Reading:



There is More than Just a Covid Variant Weighing on Investors

Dip Buying in 2021 Has Consistently Paid-Off, is it Different this Time?





EV SPAC Activity Accelerated in 2021

Why Zoom Meetings Can Leave You Fatigued

 

Sources:

https://pubs.acs.org/doi/full/10.1021/acs.nanolett.1c02868

https://news.mit.edu/2021/quantum-sensor-detect-covid-1220

 

Stay up to date. Follow us:

 

Release – Lineage Establishes Exclusive Worldwide Collaboration With Genentech

Posted on by Admin


Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders

 

  • Genentech Will Pay Lineage $50 Million Upfront
  • Eligible to Receive a Total of $670 Million in Upfront and Milestone Payments
  • Conference Call to Discuss Collaboration Planned for 8 a.m. ET

CARLSBAD, Calif.–(BUSINESS WIRE)–Dec. 20, 2021– 

Lineage Cell Therapeutics, Inc.
 (NYSE American and TASE: LCTX), today announced that Lineage and its subsidiary, 
Cell Cure Neurosciences Ltd., have entered into an exclusive worldwide collaboration and license agreement with Roche and 

Genentech
, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), for the development and commercialization of a retinal pigment epithelium (RPE) cell therapy for the treatment of ocular disorders, including advanced dry age-related macular degeneration (dry AMD) with geographic atrophy (GA).

Genentech will assume responsibility for further clinical development and commercialization of Lineage’s OpRegen program, which currently is being evaluated in a Phase 1/2a open-label, dose escalation clinical safety and efficacy study in patients with advanced dry AMD with GA. Under the terms of the collaboration agreement, Lineage will complete activities related to the ongoing clinical study, for which enrollment is complete, and perform certain manufacturing activities. 
Genentech will pay Lineage a 
$50 million upfront payment and Lineage is eligible to receive up to 
$620 million in additional development, approval and sales milestone payments, in addition to tiered double- digit royalties.

“Genentech is a clear global leader in ophthalmology and has demonstrated a longstanding commitment to patients, innovative research and successful product development,” said  Brian M. Culley, Lineage’s CEO. “Their desire to combine our cell therapy technology with their ophthalmology expertise and capabilities will help advance the OpRegen program more rapidly and we believe successfully to patients with serious ocular disorders, such as dry age-related macular degeneration. Lineage’s objective is to pioneer a new branch of regenerative medicine, based on transplanting whole cells into the body to restore activity lost to aging, injury or disease. We believe the results we have demonstrated to date with OpRegen represent a paradigm change many did not believe possible with cell therapy, by restoring retinal tissue and potentially halting or reversing the expansion of geographic atrophy. I am incredibly proud of what the Lineage team has accomplished with the OpRegen program and look forward to joining forces with the 
Genentech team as they work to take this program to the next level and potentially to patients in need of treatment.”

Mr. Culley continued, “Looking ahead, Lineage will remain focused on advancing our spinal cord injury and oncology programs as well as announcing new disease settings where we plan to deploy our technology, either on our own or through strategic alliances. All of us at Lineage are immensely proud to have the opportunity and responsibility to advance a new and exciting branch of medicine, and our aim is to make a profound impact on the patients who serve as our inspiration.”

“Genentech has a longstanding commitment to discovering and developing novel drugs for the treatment of serious eye disorders such as with advanced dry AMD with GA, which is one of our focus areas within ophthalmology,” said  James Sabry, M.D., Ph.D., global head of Pharma Partnering, Roche. “We are excited to partner with 
Lineage Cell Therapeutics to advance potential new therapies in an area of high unmet medical need.”

Conference Call Information

Lineage will host a live conference call and webcast today beginning at 
8 a.m. ET to discuss the collaboration with the Roche Group and 
Genentech. Interested parties may access the conference call by dialing (866) 888-8633 from the 
U.S. and 
Canada and (636) 812-6629 from elsewhere outside the 
U.S. and 
Canada and should request the “Lineage Cell Therapeutics Call”. A live webcast of the conference call will be available online in the Investors section of Lineage’s website. A replay of the webcast will be available on Lineage’s website for 30 days and a telephone replay will be available through 
December 27, 2021, by dialing (855) 859-2056 from the 
U.S. and 
Canada and (404) 537-3406 from elsewhere outside the 
U.S. and 
Canada and entering conference ID number 5174206.

About OpRegen

OpRegen has been developed in part through contributions and financial grants made by 
Hadasit Medical Research Services and Development Ltd. (“Hadasit”) and the 
Israeli Innovation Authority (the “IIA”). Lineage is obligated to pay a portion of upfront, milestone and royalty payments it receives to Hadasit and the IIA. OpRegen is currently being evaluated in a Phase 1/2a open-label, dose escalation safety and efficacy study of a single injection of human retinal pigment epithelium cells derived from an established pluripotent cell line and transplanted subretinally in patients with advanced dry AMD with GA. The study enrolled 24 patients into 4 cohorts. The first 3 cohorts enrolled only legally blind patients with a best corrected visual acuity (BCVA) of 20/200 or worse. The fourth cohort enrolled 12 better vision patients (BCVA from 20/65 to 20/250 with smaller mean areas of GA). Cohort 4 also included patients treated with a new “thaw-and-inject” formulation of OpRegen, which can be shipped directly to sites and used immediately upon thawing, removing the complications and logistics of having to use a dose preparation facility. The primary objective of the study was to evaluate the safety and tolerability of OpRegen as assessed by the incidence and frequency of treatment emergent adverse events. Secondary objectives are to evaluate the preliminary efficacy of OpRegen treatment by assessing the changes in ophthalmological parameters measured by various methods of primary clinical relevance. OpRegen has been well tolerated to date and there have been no new, unexpected ocular or systemic adverse events or serious adverse events related to OpRegen or study procedures that have not been previously reported.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “aim,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “can,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to the collaboration and license agreement with Roche and 
Genentech and activities expected to occur under the collaboration and license agreement, the upfront, milestone and royalty consideration payable to Lineage, the potential benefits of treatment with OpRegen, and Lineage’s plans to advance its spinal cord injury and oncology programs and announce new disease settings where it plans to deploy its technology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including the risk that competing alternative therapies may adversely impact the commercial potential of OpRegen, which could materially adversely affect the milestone and royalty payments payable to Lineage under the collaboration and license agreement, the risk that Roche and 
Genentech may not be successful in completing further clinical trials for OpRegen and/or obtaining regulatory approval for OpRegen in any particular jurisdiction, and risks and uncertainties inherent in Lineage’s business and other risks in Lineage’s filings with the 
Securities and Exchange Commission (SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the 
SEC, including Lineage’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the 
SEC and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(ir@lineagecell.com)
(442) 287-8963

Solebury Trout IR
Mike Biega
(Mbiega@soleburytrout.com)
(617) 221-9660

Russo Partners – Media Relations
Nic Johnson or  David Schull
Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com
(212) 845-4242

Source: 
Lineage Cell Therapeutics, Inc.

Release – Voyager Digital Announces Brian Brooks, Former Acting Comptroller of the U.S. Currency, Joins Board of Directors

Posted on by Admin

 


Voyager Digital Announces Brian Brooks, Former Acting Comptroller of the U.S. Currency, Joins Board of Directors

 

Research, News, and Market Data on Voyager Digital

 

Voyager Digital Ltd. (“Voyager” or the “Company”) (TSX: VOYG; OTCQX: VYGVF; FRA: UCD2), one of the fastest-growing, publicly traded cryptocurrency platforms in the United States, is pleased to announce Brian Brooks has been appointed to Voyager Digital Ltd’s Board of Directors effective immediately.
 
Philip Eytan, Chairman of Voyager Digital, said, “On behalf of the Board, I welcome Brian to the Board as an independent, non-executive Director.”  Mr. Eytan continued, “Brian’s extensive background as an executive at major crypto companies and as the leader of important government regulatory initiatives in the crypto space will help propel the growth of digital assets and Voyager’s business.”

Brian is currently CEO of Bitfury Group Ltd and was formerly the Acting Comptroller of the U.S. Currency at the Office of the Comptroller of the Currency and, before that, the Chief Legal Officer of Coinbase. Mr. Brooks has also held senior positions in the traditional finance sector, including as EVP, General Counsel and Corporate Secretary at Fannie Mae and as Vice Chairman of OneWest Bank, N.A.

Mr. Brooks is a globally recognized leader in financial services law, operations, and policy and has been instrumental in the growth of several high-profile Silicon Valley fintech startups. He most recently appeared with other crypto CEOs before the House Committee on Financial Services to discuss cryptocurrencies.  His work as Acting Comptroller leading the U.S. national banking system earned him recognition on various lists of thought leaders, including as Cointelegraph’s 13th most influential person in crypto globally; as one of Qredo’s top 20 crypto regulatory voices; and as the 10th most important influencer in the world as rated by Crunchbase.

About Voyager Digital Ltd.

Publicly traded Voyager Digital Ltd.’s (TSX: VOYG) (OTCQX:VYGVF) (FRA: UCD2) US subsidiary, Voyager Digital, LLC, is a fast-growing, cryptocurrency platform in the United States founded in 2018 to bring choice, transparency, and cost efficiency to the marketplace. Voyager offers a secure way to trade over 70 different crypto assets using its easy-to-use mobile application and earn rewards up to 12 percent annually on more than 30 cryptocurrencies. Through its subsidiary Coinify ApS, Voyager provides crypto payment solutions for both consumers and merchants around the globe. To learn more about the company, please visit https://www.investvoyager.com.
 
The TSX has not approved or disapproved of the information contained herein.
 
SOURCE Voyager Digital, Ltd.

Press Contacts
 
Voyager Digital, Ltd.
Michael Legg
Chief Communications Officer
(212) 547-8807
mlegg@investvoyager.com

Voyager Public Relations Team
pr@investvoyager.com